Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,978 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer.
Satake H, Ando K, Oki E, Shimokawa M, Makiyama A, Saeki H, Tsuji A, Mori M. Satake H, et al. Among authors: mori m. BMC Cancer. 2020 Nov 17;20(1):1116. doi: 10.1186/s12885-020-07576-9. BMC Cancer. 2020. PMID: 33203393 Free PMC article.
Comparison of computed tomography imaging analyses for evaluation after chemotherapy in patients with colorectal cancer: a retrospective pooled analysis of six phase II clinical trials.
Hirose K, Oki E, Shimose T, Sakamoto S, Sasaki S, Jogo T, Hu Q, Tsuda Y, Ando K, Nakashima Y, Saeki H, Mori M. Hirose K, et al. Among authors: mori m. Int J Clin Oncol. 2019 Nov;24(11):1397-1405. doi: 10.1007/s10147-019-01509-8. Epub 2019 Jul 22. Int J Clin Oncol. 2019. PMID: 31332611
Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B.
Yuki S, Shinozaki K, Kashiwada T, Kusumoto T, Iwatsuki M, Satake H, Kobayashi K, Esaki T, Nakashima Y, Kawanaka H, Emi Y, Komatsu Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Baba H, Mori M. Yuki S, et al. Among authors: mori m. Cancer Chemother Pharmacol. 2020 Jan;85(1):217-223. doi: 10.1007/s00280-019-03991-3. Epub 2019 Nov 25. Cancer Chemother Pharmacol. 2020. PMID: 31768696 Clinical Trial.
Efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients with stage III colon cancer (KSCC1303): final analysis of 3-year disease-free survival.
Ando K, Emi Y, Miyanari N, Tsuji A, Sakai K, Sawai T, Imamura H, Mori S, Tokunaga S, Oki E, Saeki H, Kakeji Y, Akagi Y, Baba H, Maehara Y, Mori M; Kyushu Study Group of Clinical Cancer (KSCC). Ando K, et al. Among authors: mori m, mori s. Int J Clin Oncol. 2020 Jun;25(6):1115-1122. doi: 10.1007/s10147-020-01646-5. Epub 2020 Mar 18. Int J Clin Oncol. 2020. PMID: 32189156 Clinical Trial.
A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401).
Samura H, Oki E, Okumura H, Yoshida T, Kai S, Kobayashi K, Kinjo T, Mori S, Tohyama T, Ohgaki K, Kawanaka H, Makiyama A, Ureshino N, Kotaka M, Shimose T, Ando K, Saeki H, Baba H, Maehara Y, Mori M. Samura H, et al. Among authors: mori m, mori s. Cancer Chemother Pharmacol. 2020 Aug;86(2):285-294. doi: 10.1007/s00280-020-04108-x. Epub 2020 Jul 30. Cancer Chemother Pharmacol. 2020. PMID: 32734398 Clinical Trial.
Safety and efficacy of S-1 plus oxaliplatin 130 mg/m2 combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A).
Kashiwada T, Shinozaki K, Ueno S, Kawanaka H, Uno F, Okita Y, Fukahori M, Matsushita H, Emi Y, Shimokawa M, Makiyama A, Saeki H, Oki E, Maehara Y, Mori M, Baba E; Kyushu Study Group of Clinical Cancer (KSCC). Kashiwada T, et al. Among authors: mori m. Int J Clin Oncol. 2021 Feb;26(2):345-354. doi: 10.1007/s10147-020-01803-w. Epub 2020 Oct 21. Int J Clin Oncol. 2021. PMID: 33085058 Clinical Trial.
Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.
Oki E, Makiyama A, Miyamoto Y, Kotaka M, Kawanaka H, Miwa K, Kabashima A, Noguchi T, Yuge K, Kashiwada T, Ando K, Shimokawa M, Saeki H, Akagi Y, Baba H, Maehara Y, Mori M. Oki E, et al. Among authors: mori m. Cancer Med. 2021 Jan;10(2):454-461. doi: 10.1002/cam4.3618. Epub 2020 Nov 29. Cancer Med. 2021. PMID: 33249761 Free PMC article. Clinical Trial.
Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
Miwa K, Oki E, Enomoto M, Ihara K, Ando K, Fujita F, Tominaga M, Mori S, Nakayama G, Shimokawa M, Saeki H, Baba H, Mori M, Akagi Y. Miwa K, et al. Among authors: mori m, mori s. BMC Cancer. 2021 Jan 5;21(1):23. doi: 10.1186/s12885-020-07766-5. BMC Cancer. 2021. PMID: 33402130 Free PMC article. Clinical Trial.
Monitoring FTD in the peripheral blood mononuclear cells of elderly patients with metastatic colorectal cancer administered FTD plus bevacizumab as first-line treatment.
Fujimoto Y, Oki E, Qiu S, Nakanishi R, Makiyama A, Miyamoto Y, Kotaka M, Shimokawa M, Ando K, Kimura Y, Kitao H, Maehara Y, Mori M. Fujimoto Y, et al. Among authors: mori m. Cancer Sci. 2021 Jun;112(6):2436-2441. doi: 10.1111/cas.14904. Epub 2021 May 3. Cancer Sci. 2021. PMID: 33780084 Free PMC article. Clinical Trial.
Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601.
Iwatsuki M, Orita H, Kobayashi K, Hidaka S, Arigami T, Kusumoto T, Satake H, Oki E, Tsutsumi S, Tobimatsu K, Shimokawa M, Saeki H, Makiyama A, Baba H, Mori M. Iwatsuki M, et al. Among authors: mori m. Gastric Cancer. 2022 Jan;25(1):180-187. doi: 10.1007/s10120-021-01218-0. Epub 2021 Aug 11. Gastric Cancer. 2022. PMID: 34379229 Clinical Trial.
9,978 results